Joseph E Schumacher, Abdullah Ahsan, Amber H Simpler, Adam P Natoli, Bradley J Cain, Peter S Chindavong, Aren Yarcan
{"title":"对2023年美国25个县监狱首次被捕者使用芬太尼和甲基苯丙胺的调查。","authors":"Joseph E Schumacher, Abdullah Ahsan, Amber H Simpler, Adam P Natoli, Bradley J Cain, Peter S Chindavong, Aren Yarcan","doi":"10.1186/s13722-025-00588-5","DOIUrl":null,"url":null,"abstract":"<p><p>Widespread use of fentanyl in combination with methamphetamine in carceral settings presents unique health risks and public health challenges. To contribute to continued efforts to understand drug use among first-time arrestees, this study characterizes the nature and extent of urine drug screenings (UDS) positive for fentanyl and/or methamphetamine among first-time arrestees receiving healthcare in 25 jails across the U.S. This study used the same data source, data extraction, sample selection, and UDS variables as those reported by Schumacher et al. (2025) and a similar data analytic strategy which included 81,842 arrestees with a UDS or 28.8% of total arrestees (283,884). Among first-time arrestees with complete results (43,553), 32,561 or 74.8% of arrestees tested positive for any drug and among those, 14,426 (44.3%) were positive for fentanyl and/or methamphetamine. Of those, 59.8% and 11.5% were only positive for methamphetamine or fentanyl, respectively, while 28.7% were positive for both. Demographically, individuals testing positive for both fentanyl and methamphetamine were predominantly white young adults (aged 20-39), with similar co-occurrence patterns in males and females. Fentanyl alone was more common in southern and midwestern jails and mega-sized jails, methamphetamine was more common in medium-large and southern jails, and their co-occurrence was most common in western and large jails. Approximately 97.5% of first-time arrestees tested positive for two or more drugs, with individuals testing positive for five or more drugs significantly more likely to test positive for both fentanyl and methamphetamine. This study highlights the significant prevalence of methamphetamine and/or fentanyl use among first-time arrestees, underscoring the urgent need for targeted interventions, improved in-jail substance use treatment, and post-release support to mitigate overdose risks and enhance public health outcomes.</p>","PeriodicalId":54223,"journal":{"name":"Addiction Science & Clinical Practice","volume":"20 1","pages":"57"},"PeriodicalIF":3.2000,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12288351/pdf/","citationCount":"0","resultStr":"{\"title\":\"An investigation of fentanyl and methamphetamine use among first-time arrestees from 25 county jails across the U.S. in 2023.\",\"authors\":\"Joseph E Schumacher, Abdullah Ahsan, Amber H Simpler, Adam P Natoli, Bradley J Cain, Peter S Chindavong, Aren Yarcan\",\"doi\":\"10.1186/s13722-025-00588-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Widespread use of fentanyl in combination with methamphetamine in carceral settings presents unique health risks and public health challenges. To contribute to continued efforts to understand drug use among first-time arrestees, this study characterizes the nature and extent of urine drug screenings (UDS) positive for fentanyl and/or methamphetamine among first-time arrestees receiving healthcare in 25 jails across the U.S. This study used the same data source, data extraction, sample selection, and UDS variables as those reported by Schumacher et al. (2025) and a similar data analytic strategy which included 81,842 arrestees with a UDS or 28.8% of total arrestees (283,884). Among first-time arrestees with complete results (43,553), 32,561 or 74.8% of arrestees tested positive for any drug and among those, 14,426 (44.3%) were positive for fentanyl and/or methamphetamine. Of those, 59.8% and 11.5% were only positive for methamphetamine or fentanyl, respectively, while 28.7% were positive for both. Demographically, individuals testing positive for both fentanyl and methamphetamine were predominantly white young adults (aged 20-39), with similar co-occurrence patterns in males and females. Fentanyl alone was more common in southern and midwestern jails and mega-sized jails, methamphetamine was more common in medium-large and southern jails, and their co-occurrence was most common in western and large jails. Approximately 97.5% of first-time arrestees tested positive for two or more drugs, with individuals testing positive for five or more drugs significantly more likely to test positive for both fentanyl and methamphetamine. This study highlights the significant prevalence of methamphetamine and/or fentanyl use among first-time arrestees, underscoring the urgent need for targeted interventions, improved in-jail substance use treatment, and post-release support to mitigate overdose risks and enhance public health outcomes.</p>\",\"PeriodicalId\":54223,\"journal\":{\"name\":\"Addiction Science & Clinical Practice\",\"volume\":\"20 1\",\"pages\":\"57\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-07-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12288351/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Addiction Science & Clinical Practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13722-025-00588-5\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"SUBSTANCE ABUSE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Addiction Science & Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13722-025-00588-5","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SUBSTANCE ABUSE","Score":null,"Total":0}
An investigation of fentanyl and methamphetamine use among first-time arrestees from 25 county jails across the U.S. in 2023.
Widespread use of fentanyl in combination with methamphetamine in carceral settings presents unique health risks and public health challenges. To contribute to continued efforts to understand drug use among first-time arrestees, this study characterizes the nature and extent of urine drug screenings (UDS) positive for fentanyl and/or methamphetamine among first-time arrestees receiving healthcare in 25 jails across the U.S. This study used the same data source, data extraction, sample selection, and UDS variables as those reported by Schumacher et al. (2025) and a similar data analytic strategy which included 81,842 arrestees with a UDS or 28.8% of total arrestees (283,884). Among first-time arrestees with complete results (43,553), 32,561 or 74.8% of arrestees tested positive for any drug and among those, 14,426 (44.3%) were positive for fentanyl and/or methamphetamine. Of those, 59.8% and 11.5% were only positive for methamphetamine or fentanyl, respectively, while 28.7% were positive for both. Demographically, individuals testing positive for both fentanyl and methamphetamine were predominantly white young adults (aged 20-39), with similar co-occurrence patterns in males and females. Fentanyl alone was more common in southern and midwestern jails and mega-sized jails, methamphetamine was more common in medium-large and southern jails, and their co-occurrence was most common in western and large jails. Approximately 97.5% of first-time arrestees tested positive for two or more drugs, with individuals testing positive for five or more drugs significantly more likely to test positive for both fentanyl and methamphetamine. This study highlights the significant prevalence of methamphetamine and/or fentanyl use among first-time arrestees, underscoring the urgent need for targeted interventions, improved in-jail substance use treatment, and post-release support to mitigate overdose risks and enhance public health outcomes.
期刊介绍:
Addiction Science & Clinical Practice provides a forum for clinically relevant research and perspectives that contribute to improving the quality of care for people with unhealthy alcohol, tobacco, or other drug use and addictive behaviours across a spectrum of clinical settings.
Addiction Science & Clinical Practice accepts articles of clinical relevance related to the prevention and treatment of unhealthy alcohol, tobacco, and other drug use across the spectrum of clinical settings. Topics of interest address issues related to the following: the spectrum of unhealthy use of alcohol, tobacco, and other drugs among the range of affected persons (e.g., not limited by age, race/ethnicity, gender, or sexual orientation); the array of clinical prevention and treatment practices (from health messages, to identification and early intervention, to more extensive interventions including counseling and pharmacotherapy and other management strategies); and identification and management of medical, psychiatric, social, and other health consequences of substance use.
Addiction Science & Clinical Practice is particularly interested in articles that address how to improve the quality of care for people with unhealthy substance use and related conditions as described in the (US) Institute of Medicine report, Improving the Quality of Healthcare for Mental Health and Substance Use Conditions (Washington, DC: National Academies Press, 2006). Such articles address the quality of care and of health services. Although the journal also welcomes submissions that address these conditions in addiction speciality-treatment settings, the journal is particularly interested in including articles that address unhealthy use outside these settings, including experience with novel models of care and outcomes, and outcomes of research-practice collaborations.
Although Addiction Science & Clinical Practice is generally not an outlet for basic science research, we will accept basic science research manuscripts that have clearly described potential clinical relevance and are accessible to audiences outside a narrow laboratory research field.